As of June 1 2018 JAFRAL is a part of Bio-Pharm Competence Center for Biotechnology and Pharmaceuticals.

On 20th September 2017, WHO launched report about antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis. Report shows a

JAFRAL is going to attend and co-sponsor at Viruses of Microbes 2018 in Wroclaw, Poland.

JAFRAL is going to attend and held presentation at Phage Therapy & Antibiotic Resistance 2018 in Florence, Italy. You are welcome to meet with our representative at the conference dr. Frenk Smrekar

Because there have not been rigorous clinical trials of phages, they can be used only on patients for whom all other options have failed.

Combined resistance to multiple antibiotics: a growing problem in the EU [...]

US regulators on Wednesday approved the first gene therapy against cancer - a treatment that uses a patient's own immune cells to fight leukemia - opening a new era in the fight against one of the

Scientists and physicians at University of California San Diego School of Medicine in collaboration with colleagues at the U.S. Navy Medical Research Center – Biological Defense Research Directorate

First gene therapy product could enter market in Q1 2018 The [...]

WHO: Technical Report Series 1003 published The WHO Expert Committee on [...]